FDA grants ZW25 fast-track eligibility for combined chemotherapy for her2 high expression of stomach cancer patients

recently,THE FDA
(HTTP://WWW.CHEMDRUG.COM/ARTICLE/11/)
GRANTED ZW25 FAST-TRACK ELIGIBILITY TO ACCELERATE ZW25 COMBINED CHEMOTHERAPY FOR PATIENTS WITH HIGH EXPRESSION OF HER2 GASTRIC CANCERZW25 is an important asset of Zymeworks, and fast-track eligibility will further accelerate the launch of theDrug(http://ZW25 is positioned in best-in-class, and two indications are currently in the clinical development stage, of which HER2 high expression of stomach cancer is in stage 2 clinicalOn 27 November 2018, Baiji Shenzhou acquired ZW25's exclusive development and commercialization interests in Asia (excluding Japan), Australia and New ZealandZymeworks has a unique Azymetric ™ and EFECT ™ technology platform, and ZW25 was developed based on Azymetric™ technologyZW25 targets both her2 ECD2 and ECD4 extracellular domains, target ECD4 for ScFv structure, target ECD2 as IgG structurealso noteworthy, ZW25's Fc segment has been genetically engineered, such as the knob-into-hole scheme, can effectively avoid homologous two-body, interested readers can consult thePatent(http://WO2015077891, as well as the Chinese same-ethnic patent CN105980409 A, this article will not be repeatedZW25 can target two distinct epitopes of HER2 at the same time, and is a potential Best-in-class for more effectively blocking HER2 signaling pathways and anti-tumor activity compared to traditional HER2 monoantigensAt present, ZW25 combined chemotherapy first-line treatment of stomach cancer in the 2st stage of clinical, which is the fastest development of the drug one of the indicationsAccording to official information, in 2019 ZW25 will complete phase 1 clinical, 2020 ZW25 will launch two key clinicaltrial(http://, respectively, to support ZW25 to complete the first-line stomach cancer and first-line breast cancer indications market